×
About 14,793 results

ALLMedicine™ Anxiety Disorders Center

Research & Reviews  5,072 results

Sex differences in anxiety and depression: circuits and mechanisms.
https://doi.org/10.1038/s41583-021-00513-0 10.1016/j.yfrne.2014.05.004 10.1002/mpr.1359 10.31887/DCNS.2016.18.4/ncutler 10.1016/S0165-0327(99)00158-5 10.1176/appi.ajp.157.9.1445 10.1016/j.jad.2004.09.008 10.1176/appi.ajp.160.9.1643 10.1176/appi.ajp.159.11.1848 10.1016/j.biopsych.2018.02.010 10.1038/s41583-019-0221-6 10.1016/j.neubiorev.2010.07.002 10.1186/s13293-016-0066-x 10.1016/j.yfrne.2020.100835 10.3390/diagnostics11010123 10.1016/S0091-3057(99)00139-2 10.1016/j.cobeha.2016.12.011 10.1017/S0033291707000414 10.1016/0010-440X(94)90173-2 10.1016/j.biopsych.2019.04.028 10.1111/bph.14710 10.1016/j.tins.2020.02.004 10.1016/S0140-6736(20)31561-0 10.1098/rstb.2015.0106 10.1098/rstb.2015.0119 10.1523/JNEUROSCI.5372-11.2012 10.1124/pr.115.011163 10.1210/en.2003-1504 10.1016/S0005-7967(03)00140-2 10.1037/0021-843X.109.2.290 10.1016/j.biopsych.2009.06.026 10.1007/s00424-013-1271-7 10.1016/S0091-3057(00)00392-0 10.1016/0031-9384(91)90039-Q 10.1016/j.pbb.2011.08.002 10.1016/j.cell.2016.08.067 10.3389/fnbeh.2014.00216 10.1159/000509421 10.1016/j.cell.2014.09.020 10.2741/1931 10.1016/j.arr.2005.02.002 10.1016/j.nicl.2016.10.007 10.1016/j.cpr.2007.04.009 10.1016/j.ynstr.2014.09.005 10.1038/npp.2016.174 10.1016/j.biopsych.2017.11.016 10.1038/nn.3869 10.1016/j.neuron.2014.04.042 10.1016/j.dcn.2010.10.001 10.1101/lm.70504 10.3389/fnbeh.2019.00045 10.7554/eLife.11352 10.7554/eLife.13119 10.1111/bph.12710 10.1111/bph.15341 10.1038/22761 10.1038/mp.2012.72 10.1007/s00213-015-3917-y 10.1038/mp.2013.61 10.1186/2045-5380-2-3 10.1016/j.neuroscience.2009.09.011 10.1016/j.nlm.2008.11.005 10.1186/s12888-015-0673-9 10.1038/npp.2013.338 10.1126/science.aaw7570 10.1017/S003329170500591X 10.1186/1471-244X-12-146 10.1080/15402002.2011.654296 10.1037/tra0000355 10.1037/0022-3514.77.5.1061 10.1192/bjp.158.1.59 10.1002/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.0.CO;2-N 10.1176/ajp.154.5.624 10.1176/appi.ajp.162.5.992 10.1038/mp.2008.38 10.1111/j.1749-6632.1993.tb49931.x 10.1177/0269881113490326 10.1016/S0165-0173(03)00143-7 10.1016/0306-4522(93)90507-C 10.1016/0304-3940(93)90862-F 10.1016/S0006-8993(97)00116-9 10.1016/S1054-3589(08)60863-7 10.1038/sj.npp.1300875 10.1038/mp.2010.66 10.1016/0006-8993(91)90855-P 10.1523/JNEUROSCI.2830-04.2004 10.1523/JNEUROSCI.14-05-02579.1994 10.1038/mp.2016.185 10.1016/j.tips.2007.06.006 10.1126/science.1109237 10.31887/DCNS.2016.18.4/rvalentino 10.1124/mol.112.083550 10.1016/j.physbeh.2017.09.025 10.1146/annurev.pharmtox.38.1.289 10.1210/en.2007-0705 10.1038/mp.2012.24 10.1016/j.biopsych.2017.10.012 10.1038/sj.npp.1301328 10.1016/j.tips.2013.06.004 10.1038/nrd.2017.229 10.1016/j.psychres.2010.02.001 10.1016/j.cpr.2017.05.004 10.1016/j.biopsych.2019.05.005 10.1016/j.bbr.2009.12.038 10.1016/j.yhbeh.2013.01.011 10.1016/j.cobeha.2015.11.006 10.1016/j.biopsych.2015.07.020 10.1016/j.biopsych.2015.10.007 10.1073/pnas.2011890117 10.1016/j.biopsych.2017.08.024 10.1038/npp.2011.95 10.1016/j.biopsycho.2012.02.010 10.1016/j.psyneuen.2011.03.007 10.1097/PSY.0b013e318188ade4 10.1037/rev0000033 10.1016/j.neubiorev.2005.03.021 10.1016/j.ynstr.2014.09.003 10.1038/sj.npp.1301533 10.1007/s00429-019-01875-z 10.1111/ejn.13833 10.1097/YCO.0000000000000122 10.1177/0963721412474460 10.1016/j.biopsych.2016.09.007 10.1016/j.neuroimage.2009.01.058 10.1523/JNEUROSCI.1392-15.2015 10.1016/j.biopsych.2019.08.006 10.1038/nm.4386 10.1093/ijnp/pyx048 10.1007/s00213-012-2846-2 10.1016/j.physbeh.2007.10.020 10.1016/j.neuroscience.2017.03.014 10.1016/j.biopsych.2020.05.021 10.1038/s41593-021-00806-8 10.1111/bph.14146 10.1146/annurev-genet-120215-035449 10.1016/j.semcdb.2016.04.013 10.1038/nature24265 10.1001/jama.295.12.1428 10.1007/s00429-014-0952-0 10.1016/j.neuroimage.2018.02.051 10.1186/2042-6410-4-20 10.1038/nn1325 10.1016/j.yhbeh.2009.03.010 10.1016/j.jad.2005.09.006 10.1016/j.biopsych.2020.04.013 10.1016/j.biopsych.2018.01.017 10.1016/j.biopsych.2020.12.025 10.1016/j.bbi.2015.10.003 10.1016/j.bbi.2014.05.007 10.1038/nm.2886 10.1016/j.neuroscience.2009.04.057 10.1016/j.neuroscience.2007.03.042 10.1016/j.bbr.2008.04.024 10.1523/JNEUROSCI.3630-06.2006 10.1016/j.neuropharm.2011.06.004
Nature Reviews. Neuroscience; Bangasser DA, Cuarenta A

Sep 22nd, 2021 - Epidemiological sex differences in anxiety disorders and major depression are well characterized. Yet the circuits and mechanisms that contribute to these differences are understudied, because preclinical studies have historically excluded female ...

Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications.
https://doi.org/10.1111/add.15695
Addiction (Abingdon, England); Baldwin DS

Sep 21st, 2021 - Benzodiazepines continue to be prescribed widely in the management of patients with insomnia or anxiety disorders, despite the availability and acceptability of alternative pharmacological and psychological treatments. Many patients will experienc...

The cognitive anxiety sensitivity treatment (CAST) in anxiety prevention - Focus on sep...
https://doi.org/10.1016/j.euroneuro.2021.08.265
European Neuropsychopharmacology : the Journal of the Eur... Schiele MA, Vietz M et. al.

Sep 19th, 2021 - Given the high prevalence and considerable clinical and societal burden of anxiety disorders, preventive measures are urgently warranted to reduce their incidence and overall healthcare impact. Anxiety sensitivity (AS) - a key element in learning ...

Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
https://doi.org/10.1097/PRA.0000000000000578
Journal of Psychiatric Practice; Thom RP, Alexander JL et. al.

Sep 17th, 2021 - Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed medications. They are among the first-line medications for several chronic or relapsing-remitting psychiatric conditions, including major depressive disorder an...

Treatment adequacy and remission of depression and anxiety disorders and quality of lif...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444434
Health and Quality of Life Outcomes; Lamoureux-Lamarche C, Berbiche D et. al.

Sep 17th, 2021 - Studies on the long-term outcomes of receiving adequate treatment for depression and anxiety disorders are scarce. The aims of this study were to assess the association between adequacy of care and remission of common mental disorders (CMD) and ch...

see more →

Guidelines  9 results

Perinatal Mood and Anxiety Disorders: Research and Implications for Nursing Care.
https://doi.org/10.1016/j.nwh.2021.02.003
Nursing for Women's Health; Beck CT

Jun 9th, 2021 - Perinatal Mood and Anxiety Disorders: Research and Implications for Nursing Care.|2021|Beck CT,|

Perinatal Mood and Anxiety Disorders: Research and Implications for Nursing Care.
https://doi.org/10.1016/j.jogn.2021.02.007
Journal of Obstetric, Gynecologic, and Neonatal Nursing :... Beck CT

Jun 9th, 2021 - Perinatal Mood and Anxiety Disorders: Research and Implications for Nursing Care.|2021|Beck CT,|

Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescent...
https://doi.org/10.1016/j.jaac.2020.05.005
Journal of the American Academy of Child and Adolescent P... Walter HJ, Bukstein OG et. al.

May 23rd, 2020 - Anxiety disorders are among the most common psychiatric disorders in children and adolescents. As reviewed in this guideline, both cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitor (SSRI) medication have considerable em...

Clinical Updates in Women's Health Care Summary: Mood and Anxiety Disorders: Primary an...
https://doi.org/10.1097/AOG.0000000000002295
Obstetrics and Gynecology; Osborne LM, Payne JL

Aug 24th, 2017 - The management of psychiatric disorders in women is complicated by reproductive life cycle events. Psychiatric disorders can be initiated or exacerbated during times of hormonal change (such as menarche, the premenstrual period, the postpartum per...

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908
Clinical Pharmacology and Therapeutics; Hicks JK, Bishop JR et. al.

May 15th, 2015 - Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summar...

see more →

Drugs  447 results see all →

News  387 results

Insomnia in Kids Tied to Mood, Anxiety Disorders in Adulthood
https://www.medscape.com/viewarticle/953149

Jun 15th, 2021 - Insomnia in childhood persists into adulthood and may raise the risk for internalizing disorders in young adults, new research indicates. However, insomnia symptoms in childhood that remit in the transition to adolescence do not confer increased r...

Adult Separation Anxiety Raises Suicidality Risk
https://www.medscape.com/viewarticle/949020

Apr 8th, 2021 - Separation anxiety plays a substantial role in suicidality in patients with mood and anxiety disorders, new research suggests. Results of a study that included 500 outpatients with mood or anxiety disorders showed adult separation anxiety disorder...

Five-Minute Screen in Toddlers Predicts Subsequent Anxiety
https://www.medscape.com/viewarticle/948364

Mar 30th, 2021 - A five-minute, easy-to-administer screen in toddlers accurately predicts subsequent anxiety, providing an opportunity for early intervention to head off this potentially debilitating disorder. Investigators found the Fear and Shyness scales of the...

Erectile Dysfunction Prevalence High in Patients with Anxiety Disorders
https://www.medscape.com/viewarticle/946842

Mar 4th, 2021 - Takeaway This review found a high prevalence of erectile dysfunction (ED) in the anxiety disorder population and evidence that suggest ED may be more severe in this population. However, the evidence was limited because of the high heterogeneity be...

Opioid Prescribing for High-Risk Patients Continues to Rise
https://www.medscape.com/viewarticle/942287

Dec 9th, 2020 - Since the publication of the Centers for Disease Control and Prevention's (CDC's) opioid guideline in March 2016, there has been a substantial drop in the prescription rate for these medications ― except for patients at highest risk for opioid abu...

see more →

Patient Education  2 results see all →